Factory Mutual Insurance Co. lessened its position in shares of Express Scripts Holding (NASDAQ:ESRX) by 27.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 546,248 shares of the company’s stock after selling 207,100 shares during the period. Factory Mutual Insurance Co.’s holdings in Express Scripts were worth $40,773,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of ESRX. Oliver Luxxe Assets LLC bought a new position in shares of Express Scripts in the 4th quarter worth $3,484,000. Hills Bank & Trust Co. increased its holdings in shares of Express Scripts by 3.5% in the 4th quarter. Hills Bank & Trust Co. now owns 30,791 shares of the company’s stock worth $2,298,000 after buying an additional 1,028 shares during the last quarter. Atria Investments LLC increased its holdings in shares of Express Scripts by 10.3% in the 4th quarter. Atria Investments LLC now owns 12,340 shares of the company’s stock worth $921,000 after buying an additional 1,157 shares during the last quarter. Hexavest Inc. increased its holdings in shares of Express Scripts by 1.1% in the 4th quarter. Hexavest Inc. now owns 500,235 shares of the company’s stock worth $37,338,000 after buying an additional 5,366 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Express Scripts by 8.1% in the 4th quarter. Nisa Investment Advisors LLC now owns 233,538 shares of the company’s stock worth $17,431,000 after buying an additional 17,441 shares during the last quarter. 88.21% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages have recently commented on ESRX. Robert W. Baird reissued a “buy” rating and issued a $92.00 price target (up previously from $81.00) on shares of Express Scripts in a report on Tuesday, January 9th. SunTrust Banks reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Express Scripts in a research note on Friday. ValuEngine raised shares of Express Scripts from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Royal Bank of Canada initiated coverage on shares of Express Scripts in a research note on Tuesday, September 19th. They issued a “sector perform” rating and a $68.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Express Scripts in a research note on Thursday, December 21st. Five analysts have rated the stock with a sell rating, ten have assigned a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. Express Scripts currently has an average rating of “Hold” and a consensus price target of $77.09.
Shares of Express Scripts Holding (ESRX) traded up $0.78 on Tuesday, reaching $80.87. 3,156,200 shares of the company’s stock traded hands, compared to its average volume of 3,964,000. The stock has a market cap of $45,800.00, a PE ratio of 13.43, a P/E/G ratio of 0.89 and a beta of 0.87. The company has a quick ratio of 0.61, a current ratio of 0.73 and a debt-to-equity ratio of 0.86. Express Scripts Holding has a fifty-two week low of $55.80 and a fifty-two week high of $81.75.
Express Scripts (NASDAQ:ESRX) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.90 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.90. The business had revenue of $24.68 billion during the quarter, compared to analysts’ expectations of $25.68 billion. Express Scripts had a net margin of 3.64% and a return on equity of 25.46%. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.74 EPS. analysts predict that Express Scripts Holding will post 7.04 earnings per share for the current fiscal year.
Express Scripts announced that its Board of Directors has authorized a stock buyback plan on Monday, December 18th that permits the company to buyback 45,000,000 shares. This buyback authorization permits the company to buy shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.
In other news, CEO Timothy C. Wentworth purchased 8,000 shares of the company’s stock in a transaction on Tuesday, October 31st. The stock was acquired at an average price of $61.13 per share, with a total value of $489,040.00. Following the transaction, the chief executive officer now directly owns 98,628 shares of the company’s stock, valued at approximately $6,029,129.64. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Christine Houston sold 10,104 shares of the stock in a transaction on Friday, December 15th. The shares were sold at an average price of $70.08, for a total transaction of $708,088.32. Following the sale, the vice president now directly owns 87,400 shares of the company’s stock, valued at approximately $6,124,992. The disclosure for this sale can be found here. Insiders have sold a total of 17,644 shares of company stock valued at $1,289,609 in the last three months. 0.68% of the stock is currently owned by corporate insiders.
Express Scripts Profile
Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).
Want to see what other hedge funds are holding ESRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Express Scripts Holding (NASDAQ:ESRX).
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.